Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM) Featured in Virtual Coverage of the Summer Investor Summit 2020
Bellicum (NASDAQ: BLCM) is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum's lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. For more information, visit the company's website at www.bellicum.com To view IBN’s virtual coverage of the Summer Investor Summit, visit http://IBN.fm/InvestorSummitSummer2020 About InvestorBrandNetwork’s Virtual Coverage The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online…







